| Year |
Citation |
Score |
| 2008 |
Uttamsingh S, Bao X, Nguyen KT, Bhanot M, Gong J, Chan JL, Liu F, Chu TT, Wang LH. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene. 27: 2626-34. PMID 17982486 DOI: 10.1038/Sj.Onc.1210915 |
0.496 |
|
| 2003 |
Uttamsingh S, Zong CS, Wang LH. Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 Is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts. The Journal of Biological Chemistry. 278: 18798-810. PMID 12646574 DOI: 10.1074/Jbc.M211522200 |
0.723 |
|
| 2002 |
Nguyen KT, Zong CS, Uttamsingh S, Sachdev P, Bhanot M, Le MT, Chan JL, Wang LH. The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation. The Journal of Biological Chemistry. 277: 11107-15. PMID 11799110 DOI: 10.1074/Jbc.M108166200 |
0.421 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2017 |
Jimeno A, Gordon MS, Chugh R, Messersmith W, Mendelson DS, Dupont J, Stagg RJ, Kapoun AM, Xu L, Uttamsingh S, Brachmann R, Smith DC. A first-in-human Phase 1 study of the anti-cancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28954784 DOI: 10.1158/1078-0432.CCR-17-2157 |
0.161 |
|
| 2020 |
Dotan E, Cardin DB, Lenz HJ, Messersmith WA, O'Neil BH, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM, Brachmann R, Uttamsingh S, Stagg R, Weekes CD. Phase 1b study of Wnt inhibitor ipafricept (IPA) with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer (mPDAC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32694153 DOI: 10.1158/1078-0432.CCR-20-0489 |
0.157 |
|
| 2016 |
Weekes C, Berlin J, Lenz H, O'Neil B, Messersmith W, Cohen S, Dendinger C, Shahda S, Kapoun A, Zhang C, Jenner R, Cattaruzza F, Xu L, Dupont J, Brachmann R, ... Uttamsingh S, et al. Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Annals of Oncology. 27: vi117. DOI: 10.1093/annonc/mdw368.10 |
0.147 |
|
| 2022 |
Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, et al. Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Ejhaem. 3: 139-153. PMID 35846221 DOI: 10.1002/jha2.375 |
0.122 |
|
| 2020 |
Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun AM, Xu L, Stagg B, Uttamsingh S, Brachmann RK, Farooki A, Mita M. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Research and Treatment. PMID 32803633 DOI: 10.1007/s10549-020-05817-w |
0.105 |
|
| 2020 |
Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, et al. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. The Lancet. Haematology. PMID 32758434 DOI: 10.1016/S2352-3026(20)30208-8 |
0.062 |
|
| 2019 |
Dotan E, Cardin DB, Lenz H, Messersmith WA, O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Kapoun AM, Brachmann RK, Uttamsingh S, Weekes CD. Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC). Journal of Clinical Oncology. 37: 369-369. DOI: 10.1200/JCO.2019.37.4_SUPPL.369 |
0.059 |
|
| 2022 |
Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, ... ... Uttamsingh S, et al. Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. Ejhaem. 3: 394-405. PMID 35846031 DOI: 10.1002/jha2.394 |
0.036 |
|
| Hide low-probability matches. |